Please login to the form below

Not currently logged in
Email:
Password:

Chase Pharmaceuticals appoints former Allergan president

Douglas Ingram joins as chief executive officer
Douglas Ingram

Washington-based Chase Pharmaceuticals has appointed Douglas Ingram as its new chief executive officer to replace John Siebert, who will continue working with the company in an advisory capacity.

He brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership.

Prior to serving as president of Allergan, Ingram directed the company's operations in Europe, the Middle East and Africa and was responsible for various aspects of its global organisation including regulatory affairs and external communications.

Ingram said: “I am privileged to lead Chase Pharmaceuticals as we execute an elegant approach to the development of new Alzheimer's treatments.

“Our goal is to build a strong CNS biopharmaceutical company to improve the lives of the millions of patients and their families burdened by this devastating disease. We have an important mission and I am excited to play a leadership role in this journey.”

As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's disease.

Greg Parekh, chairman of Chase Pharmaceuticals, said: “Doug has a proven track record of disruptive approaches, building strong teams and delivering above-market performance … I am confident that Doug will successfully develop Chase to its fullest potential.”

15th December 2015

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....